Gilead Sciences, Inc. $GILD Shares Sold by Eastern Bank

Eastern Bank decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 23.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 825 shares of the biopharmaceutical company’s stock after selling 250 shares during the quarter. Eastern Bank’s holdings in Gilead Sciences were worth $91,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD raised its stake in shares of Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after buying an additional 11,156,382 shares during the period. Nuveen LLC acquired a new position in Gilead Sciences during the first quarter worth $620,415,000. Kingstone Capital Partners Texas LLC acquired a new position in Gilead Sciences during the second quarter worth $238,083,000. Los Angeles Capital Management LLC raised its position in Gilead Sciences by 422.6% during the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after acquiring an additional 2,040,261 shares during the period. Finally, Vanguard Group Inc. raised its position in Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after acquiring an additional 1,942,433 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $117.18 on Monday. Gilead Sciences, Inc. has a one year low of $84.17 and a one year high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock has a market cap of $145.40 billion, a PE ratio of 23.34, a P/E/G ratio of 0.80 and a beta of 0.34. The stock has a 50 day moving average price of $114.65 and a 200 day moving average price of $110.25.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same period last year, the company earned $2.01 EPS. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a dividend of $0.79 per share. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. UBS Group upped their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Rothschild & Co Redburn increased their price objective on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Finally, Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a research note on Friday, July 25th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $118.08.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider directly owned 113,193 shares of the company’s stock, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their position. The disclosure for this sale can be found here. Insiders sold 77,000 shares of company stock worth $8,853,430 in the last 90 days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.